<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861987</url>
  </required_header>
  <id_info>
    <org_study_id>PCS6422-GI-01</org_study_id>
    <nct_id>NCT04861987</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors</brief_title>
  <official_title>A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of Fixed-dose PCS6422 With Escalating Doses of Capecitabine Administered Orally to Patients With Advanced, Refractory Gastrointestinal Tract Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Processa Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Processa Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open label, multicenter study in patients who have advanced, relapsed&#xD;
      refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies&#xD;
      who, in the judgment of investigators, are candidates for fluoropyrimidine monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">March 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent Adverse Events as assessed by CTCAE v5.0</measure>
    <time_frame>~6 months</time_frame>
    <description>Frequency, duration, and severity of treatment-emergent adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of capecitabine</measure>
    <time_frame>~14 days</time_frame>
    <description>To evaluate the Maximum Plasma Concentration (Cmax) of capecitabine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of PCS6422</measure>
    <time_frame>~14 days</time_frame>
    <description>To evaluate the Maximum Plasma Concentration (Cmax) of PCS6422</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events of Special Interest as assessed by CTCAE v5.0</measure>
    <time_frame>~6 months</time_frame>
    <description>Frequency, duration, and severity of adverse events of special interest (AESIs)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Refractory Cancer</condition>
  <condition>Tumor Gastric</condition>
  <arm_group>
    <arm_group_label>PCS6422 + Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose of PCS6422 combined with various doses of Capecitabine administered in 14 day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCS6422 and capecitabine</intervention_name>
    <description>PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.</description>
    <arm_group_label>PCS6422 + Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has advanced, metastatic or unresectable GI tract tumors that are refractory or&#xD;
             intolerant to existing available therapies and for whom the investigator recommends&#xD;
             fluoropyrimidine monotherapy.&#xD;
&#xD;
          2. Has measurable disease in accordance with Respond Evaluation Criteria in Solid Tumors&#xD;
             (RECIST) guidelines (Version 1.1).&#xD;
&#xD;
          3. Is aged ≥18 years&#xD;
&#xD;
          4. Has not received treatment with intravenous (IV) 5 FU or oral 5 FU analogs in the 4&#xD;
             weeks preceding enrollment&#xD;
&#xD;
          5. Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 at study entry&#xD;
&#xD;
          6. Has adequate bone marrow, liver, and renal function as assessed by the following&#xD;
             laboratory requirements conducted within 7 days before starting study treatment:&#xD;
&#xD;
               1. peripheral ANC of ≥1.5 × 109/L&#xD;
&#xD;
               2. platelet count of ≥75 × 109/L without growth factor/transfusion&#xD;
&#xD;
               3. hemoglobin ≥8.5 g/dL without growth factor/transfusion&#xD;
&#xD;
               4. estimated glomerular filtration rate &gt;50 mL/min&#xD;
&#xD;
               5. total bilirubin &lt;2 × upper limit of normal (ULN); &lt;5 × ULN if patient has liver&#xD;
                  metastases, biliary tract cancer; or ≤3 × ULN if the patient has Gilbert's&#xD;
                  disease&#xD;
&#xD;
               6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &lt;2.5 × ULN,&#xD;
                  with liver metastasis &lt;5 × ULN&#xD;
&#xD;
               7. international normalized ratio (INR) &lt;1.5&#xD;
&#xD;
          7. Has a life expectancy of at least 12 weeks&#xD;
&#xD;
          8. Female patients of childbearing potential and male patients with partners capable of&#xD;
             reproduction must agree to use an effective contraceptive method from the time of&#xD;
             Screening through 60 days after the last dose of capecitabine&#xD;
&#xD;
          9. Females of childbearing potential must have a negative serum pregnancy β human&#xD;
             chorionic gonadotropin pregnancy test result&#xD;
&#xD;
         10. Willingly provides written, informed consent.&#xD;
&#xD;
         11. Has resolution or stabilization of acute toxicity from prior therapy to Grade &lt;2 -&#xD;
             except Grade 2 neuropathy&#xD;
&#xD;
         12. If patient has human immune deficiency virus (HIV) infection, it is controlled with&#xD;
             undetectable viral load with antiretroviral treatment.&#xD;
&#xD;
         13. If patient has hepatitis C infection and received antiviral treatment, has a negative&#xD;
             viral load at Screening&#xD;
&#xD;
         14. If patient has chronic hepatitis B infection and is receiving antiviral treatment, has&#xD;
             a negative viral load at Screening.&#xD;
&#xD;
         15. Is willing and able to comply with all protocol required visits and assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is unable to take oral medication or malabsorption syndromes potentially interfering&#xD;
             with medication absorption (e.g., short bowel syndrome or chronic, partial bowel&#xD;
             obstruction)&#xD;
&#xD;
          2. Has history or presence of clinically significant abnormal 12 lead ECG results, in the&#xD;
             investigator's opinion&#xD;
&#xD;
          3. Has current brain metastasis&#xD;
&#xD;
          4. Has prolonged QTc (with Fridericia's correction) of &gt;480 msec in men and women&#xD;
             performed at Screening&#xD;
&#xD;
          5. Has a history of prolonged QTc interval, ventricular tachycardia/fibrillation or&#xD;
             significant ventricular arrhythmia, or Torsades de Pointes, or a history of&#xD;
             ventricular ablation for arrhythmia&#xD;
&#xD;
          6. Has congenital long QT syndrome or a family history of long QT syndrome&#xD;
&#xD;
          7. Has other clinically significant cardiac disease including, but not limited to,&#xD;
             uncontrolled angina, myocardial ischemia or infarction within 6 months, congestive&#xD;
             heart failure &gt;Class II per the New York Heart Association, or history of myocarditis&#xD;
&#xD;
          8. Has an electrolyte disturbance, such as uncorrected hypokalemia/hyperkalemia,&#xD;
             hypomagnesemia, or hypocalcemia. Patients can be enrolled following successful&#xD;
             correction of an electrolyte disturbance.&#xD;
&#xD;
          9. Is currently using any drugs included in the prohibited medications list in the&#xD;
             protocol (including those that can prolong QTc) that cannot be discontinued&#xD;
&#xD;
         10. Has known hypersensitivity to any of the components of study treatments&#xD;
&#xD;
         11. Has other primary cancer requiring treatment within the last 3 years, except for&#xD;
             cervical intraepithelial neoplasia, ductal carcinoma in situ, or completely excised&#xD;
             squamous or basal cell carcinoma&#xD;
&#xD;
         12. Is a pregnant or lactating female&#xD;
&#xD;
         13. Had major surgery, open biopsy, or significant traumatic injury within 4 weeks prior&#xD;
             to the first dose of study treatment&#xD;
&#xD;
         14. Is receiving or has received any investigational treatment within 4 weeks prior to&#xD;
             study entry, or participating in another clinical study&#xD;
&#xD;
         15. Has known DPD deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sian Bigora, Pharm. D</last_name>
    <role>Study Director</role>
    <affiliation>Processa Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Nyberg</last_name>
    <phone>443-776-3133</phone>
    <email>mnyberg@processapharmaceuticals.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debbie Vidlak</last_name>
      <phone>402-559-7507</phone>
      <email>dvidlak@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jean Grem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahsan Khan</last_name>
      <phone>732-235-3458</phone>
      <email>ark140@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Boland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Sloan</last_name>
      <phone>505-913-8933</phone>
      <email>olivia.sloan@nmcancercare.com</email>
    </contact>
    <investigator>
      <last_name>Oliver Rixe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Ghalib</last_name>
      <phone>718-405-8527</phone>
      <email>mhghalib@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Sanjay Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Goldberg</last_name>
      <email>sharon.goldberg@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Capecitabine</keyword>
  <keyword>Eniluracil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

